SEK 0.82
(-3.55%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 40.68 Million SEK | 30.44% |
2022 | 31.19 Million SEK | 30.0% |
2021 | 23.99 Million SEK | -45.6% |
2020 | 44.11 Million SEK | 185.64% |
2019 | 15.44 Million SEK | 2.55% |
2018 | 15.05 Million SEK | 57.69% |
2017 | 9.55 Million SEK | -26.27% |
2016 | 12.95 Million SEK | 168.65% |
2015 | 4.82 Million SEK | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | 32.27 Million SEK | -20.69% |
2024 Q2 | 32.27 Million SEK | 0.0% |
2023 Q3 | 40.68 Million SEK | -16.16% |
2023 Q4 | 40.68 Million SEK | 0.0% |
2023 Q1 | 48.53 Million SEK | 55.58% |
2023 Q2 | 48.53 Million SEK | 0.0% |
2023 FY | 40.68 Million SEK | 30.44% |
2022 Q4 | 31.19 Million SEK | 0.0% |
2022 Q3 | 31.19 Million SEK | -25.63% |
2022 Q2 | 41.94 Million SEK | 0.0% |
2022 Q1 | 41.94 Million SEK | 74.81% |
2022 FY | 31.19 Million SEK | 30.0% |
2021 Q1 | 33.85 Million SEK | -23.25% |
2021 Q3 | 23.99 Million SEK | -29.13% |
2021 FY | 23.99 Million SEK | -45.6% |
2021 Q4 | 23.99 Million SEK | 0.0% |
2021 Q2 | 33.85 Million SEK | 0.0% |
2020 Q4 | 44.11 Million SEK | 0.0% |
2020 Q2 | 21.07 Million SEK | -0.0% |
2020 Q1 | 21.08 Million SEK | 36.5% |
2020 FY | 44.11 Million SEK | 185.64% |
2020 Q3 | 44.11 Million SEK | 109.26% |
2019 Q1 | - SEK | 0.0% |
2019 FY | 15.44 Million SEK | 2.55% |
2019 Q4 | 15.44 Million SEK | -0.0% |
2019 Q2 | 22.56 Million SEK | 0.0% |
2019 Q3 | 15.44 Million SEK | -31.56% |
2018 FY | 15.05 Million SEK | 57.69% |
2017 FY | 9.55 Million SEK | -26.27% |
2016 FY | 12.95 Million SEK | 168.65% |
2015 FY | 4.82 Million SEK | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Acarix AB (publ) | 62.88 Million SEK | 35.299% |
ADDvise Group AB (publ) | 3.28 Billion SEK | 98.762% |
ADDvise Group AB (publ) | 3.28 Billion SEK | 98.762% |
Arcoma AB | 81.96 Million SEK | 50.359% |
Bactiguard Holding AB (publ) | 682.87 Million SEK | 94.042% |
BICO Group AB (publ) | 10.19 Billion SEK | 99.601% |
Boule Diagnostics AB (publ) | 755.1 Million SEK | 94.612% |
CellaVision AB (publ) | 928.71 Million SEK | 95.619% |
Clinical Laserthermia Systems AB (publ) | 57.72 Million SEK | 29.516% |
Chordate Medical Holding AB (publ) | 21.95 Million SEK | -85.314% |
C-Rad AB (publ) | 404 Million SEK | 89.929% |
Duearity AB (publ) | 15.14 Million SEK | -168.665% |
Dignitana AB (publ) | 44.83 Million SEK | 9.244% |
Episurf Medical AB (publ) | 104.3 Million SEK | 60.991% |
Getinge AB (publ) | 55.09 Billion SEK | 99.926% |
Scandinavian Real Heart AB (Publ) | 102.63 Million SEK | 60.359% |
Iconovo AB (publ) | 128.07 Million SEK | 68.233% |
Integrum AB (publ) | 164.85 Million SEK | 75.32% |
Mentice AB (publ) | 322.52 Million SEK | 87.385% |
OssDsign AB (publ) | 356.38 Million SEK | 88.584% |
Paxman AB (publ) | 167.12 Million SEK | 75.655% |
Promimic AB (publ) | 92.87 Million SEK | 56.192% |
Qlife Holding AB (publ) | 39.04 Million SEK | -4.202% |
SciBase Holding AB (publ) | 64.33 Million SEK | 36.757% |
ScandiDos AB (publ) | 81.47 Million SEK | 50.061% |
Sectra AB (publ) | 3.21 Billion SEK | 98.733% |
Sedana Medical AB (publ) | 1.01 Billion SEK | 95.988% |
Senzime AB (publ) | 433.54 Million SEK | 90.615% |
SpectraCure AB (publ) | 144.83 Million SEK | 71.908% |
Stille AB | 804.89 Million SEK | 94.945% |
Vitrolife AB (publ) | 16.39 Billion SEK | 99.752% |
Xvivo Perfusion AB (publ) | 2.19 Billion SEK | 98.147% |